Drug Companies

Drug companies loom as the pricing juggernauts at the AIDS summit's heart, their sky-high costs igniting reporter assaults on C.J.—slash prices or defend U.S. patents?—while Toby explodes over grotesque disparities like Norway versus Burundi. Collectively, they form the antagonist industry targeted by White House pressure, humanitarian outrage, and policy clashes, blocking affordable access to life-saving medicines for African nations in a storm of moral and diplomatic fury.